DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Nihonbashi Life Science Building - Hall 201

2025年12月16日 (火) 午前 10:00 - 2025年12月17日 (水) 午後 6:10

2-3-11 Nihonbashi-honcho, Chuo-ku, Tokyo, 103-0023 Japan

10th DIA Cell and Gene Therapy Products Symposium in Japan

10th Anniversary Symposium - Shaping Our Future -

概要

10th DIA Cell and Gene Therapy Products Symposium in Japan

  10th Anniversary Symposium  - Shaping Our Future -

 

Healthcare continues to evolve, with advances in medical technology constantly driven by both academic exploration and the demands of society. For the past ten years, experts from industry, academia, and government have discussed the future of cell and gene therapy in Japan at this symposium from the regulatory, technology, and business perspectives. Some of these visions of the future that we have discussed have already become reality and are now evolving into the future’s next phase.
This year’s symposium will continue to provide a “forum for dialogue” to envision, through our discussions, future expansions in cell and gene therapy products and to share current issues and guidelines for the future. We are planning these five sessions to analyze the current status of cell therapy and gene therapy from various perspectives and create a vision for their future with you. By sharing our latest results and knowledge through these sessions, we hope to envision “shaping our future” together with you.

  • Establishing a mature ecosystem for new modalities : Lessons learned from precedent success cases
  • Ten years of history and the future : Let’s ask the past chairmans (Memorial Session)
  • Human resources who will shape the future of regenerative medicine : Co-creation by expertise and bird’s eye view
  • Stable manufacturing of cellular therapeutic products : Consistent manufacturing processes throughout the product life cycle
  • Realizing the true value of the conditional and time-limited approval system

In addition, key opinion leaders responsible for cell therapy and gene therapy research and development programs from academia and industry, as well as government / regulatory officials, will be invited to deliver the latest information and topics through keynote lectures and other sessions.
This symposium will be held in a hybrid format. To provide a more focused location for personal dialogue, we will prepare a venue for face-to-face participation at the Nihonbashi Life Science Building along with a networking event for the free exchange of opinions. To make this symposium available to as many people as possible, participants will be able to choose to participate in person or online. Lecture materials and videos will be distributed to attendees after the symposium.
We look forward to your participation.
* Please note that there may be restrictions on recording and sharing materials based on the content and nature of each session or lecture.

 

View Program

Featured

Want to learn more about 10th DIA Cell and Gene Therapy Products Symposium in Japan? You've come to the right site!

プログラム委員会

  • Kiyoshi  Okada, MD, PhD
    Kiyoshi Okada, MD, PhD Professor , Deputy Director, Regenerative Medicine Support Office, Future Medica
    the University of Osaka & the University of Osaka Hospital, Japan
  • Yasuko  Terao, PhD
    Yasuko Terao, PhD Head, External Scientific Engagement, R&D Japan Region,
    Takeda Pharmaceutical Co., Ltd., Japan
  • Hiroyuki  Suda, MSc
    Hiroyuki Suda, MSc VP, Clinical Development Strategy
    KORTUC Inc., Japan
  • Akiyo  Fujikawa
    Akiyo Fujikawa Senior Director of Regulatory Affairs
    Aurion Biotech Japan, LLC, Japan
  • Ryutaro  Hirasawa
    Ryutaro Hirasawa CMC Regulatory Affairs, Associate Director
    Daiichi Sankyo Co., Ltd., Japan
  • Akiko  Ikeda, RPh
    Akiko Ikeda, RPh PRIMO, External Researcher/Consultant
    National Cancer Center, Japan
  • Ikuo  Kawauchi
    Ikuo Kawauchi Senior Expert,International Standards Promotion Office,Intellectual Property Div
    FUJIFILM Holdings Corporation, Japan
  • Akihiro  Kume
    Akihiro Kume Advisor, Corporate Planning Office
    RPM Co., Ltd, Japan
  • Keiji  Miyamoto
    Keiji Miyamoto Principal Post-Marketing Regulatory Affairs Dep.
    Daiichi Sankyo Co.,Ltd., Japan
  • Sumimasa  Nagai, MD, PhD
    Sumimasa Nagai, MD, PhD Institute for Advancement of Clinical and Translational Science(iACT)
    Kyoto University Hospital, Japan
  • Atsushi  Nishikawa
    Atsushi Nishikawa Reviewer, Office of Cellular and Tissue-based Products
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Gentaro  Tajima, MS
    Gentaro Tajima, MS Director, Regulatory Affairs
    Ultragenyx Japan K.K., Japan
  • Maki  Tanaka
    Maki Tanaka General Manager, Project Management Department
    Takara Bio Inc., Japan
  • Yoshie  Tsurumaki
    Yoshie Tsurumaki
    HEALIOS K.K., Japan
  • Satoshi  Yasuda, PhD
    Satoshi Yasuda, PhD Head, Division of Cell-Based Therapeutic Products
    National Institute of Health Sciences, Japan
  • Mika  Yoshimatsu
    Mika Yoshimatsu Head of CMC Development
    T Cell Nouveau Inc., Japan
  • Ayaha  Kuriyama
    Ayaha Kuriyama
    National Cancer Center Hospital, Japan
  • Futaba  Nagata
    Futaba Nagata
    PPG Service, Japan
  • Hiroto  Asou
    Hiroto Asou Reviewer, Office of New Drug IV
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。